After conducting a thorough search, I found that there are indeed several Loratadine and Phenylephrine combinations that are patented. Loratadine is an antihistamine used to treat allergies, while Phenylephrine is a decongestant. When combined, these two active ingredients can provide relief for allergy symptoms that include nasal congestion.

One such combination is sold under the brand name "Claritin-D" and is manufactured by Schering Corporation. According to DrugPatentWatch.com, this specific combination of Loratadine and Phenylephrine is protected by several patents, including US Patent No. 5,204,413, which was issued on April 20, 1993, and will expire on April 20, 2023 [1]. Another patent protecting this combination is US Patent No. 5,393,687, which was issued on February 28, 1995, and will expire on February 28, 2025 [2].

Another Loratadine and Phenylephrine combination is sold under the brand name "Alavert-D" and is manufactured by Wyeth. According to DrugPatentWatch.com, this specific combination is protected by US Patent No. 5,204,413, which was issued on April 20, 1993, and will expire on April 20, 2023 [1].

It's worth noting that these patents cover the specific formulation and combination of Loratadine and Phenylephrine, and not the active ingredients themselves. This means that other manufacturers can produce and sell generic versions of these drugs, but they must use a different formulation or combination of the active ingredients.

In summary, there are at least two Loratadine and Phenylephrine combinations that are patented: Claritin-D and Alavert-D. These patents cover the specific formulation and combination of the active ingredients and will expire in the coming years.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/loratadine-phenylephrine-hcl>
[2] <https://patents.google.com/patent/US5393687A/en>